| |
| . |
 24  1/2  |
|
|
|
Subject |
Hyundai Pharm. Confirmed to Receive Ministry of Health and Human Services Funding for Novel Drug Substance Development |
Content |
Novel Type 2 Diabetes Treatment Drug Substance (HD-6277) appointed as Hyundai Pharm. Confirmed to Receive Ministry of Health and Human Services Funding for Novel Drug Substance Development
Hyundai Pharm. Plans to Invest 1.6 Million USD in Research including Government Funding for the next 2 years.
The novel Type 2 Diabetes oral treatment development project (GPR 40 agonist) from Hyundai Pharm (President Yeong Hak Kim) is looking forward to be fostered to become a new growth engine of domestic pharmaceutical industry with the continuous government funding.
On 12th, Hyundai Pharm entered development support agreement with the Ministry of Health and Wellness for HD-6277, Novel Type 2 Diabetes Treatment Drug Substance.
Previously, this project for synthetic procedure for toxicology study before clinical studies have been supported by the New Drug Development Business Group; now with this agreement, Hyundai Pharm secured support for clinical study approval application. By October 2016, Hyundai Pharm plans to develop HD-6277 with 1.6 Million USD including support from government funding.
HD-6277, which controls insulin secretion in our body, is very effective in blood glucose control with just once a daily administration and is currently developing a low safety profile drug compared to other side effects such as low blood glucose.
Hyundai Pharm is leading the way for Type 2 Diabetes treatment development via GPR119 receptor agonist project selected as “continued challenges” business from Excellence Technology Center (ATC) and enhancement in continuous new drug development study capability.
|
Date |
2014-11-13 |
|
 |
 |
 |
|
